Author

Seimia Chebbi

Division of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland;

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

Alexandra BomaneiD· 1 shared Alvaro A. MartineziD· 1 shared Axel FinckhiD· 1 shared Baptiste MouyssetiD· 1 shared Burkhard Moeller· 1 shared Cem Gabay· 1 shared Chen BuxbaumiD· 1 shared Delphine S Courvoisier· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexandra BomaneORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Serum Calprotectin as predictor of Rheumatoid Arthritis disease severity and Mortality

Seimia Chebbi, Denis Mongin, Delphine S Courvoisier, Michael J Nissen, Burkhard Moeller, Raphael Micheroli, Cem Gabay, Nicolas Vuilleumier, Axel Finckh, Matthias Jarlborg

This study evaluates serum calprotectin as a biomarker for disease activity, severity, cardiovascular risk, and mortality in inflammatory rheumatic diseases, finding it to be a better predictor than CRP in certain contexts.

bioRxiv · Nov 3, 2026 · PreprintImmunology

Reverse molecular pharmacology identifies the non-canonical axis of IRAK as a chemoresistance factor in neuroblastoma

Marion Le Grand, Chen Buxbaum, Mathilde Kerhervé, Flavie Gaucher, Alvaro A. Martinez, Mohammed Taha, Kévin Müller, Baptiste Mouysset, Alexandra Bomane, Sébastien Letard, Tim W. Failes, Greg M. Arndt, Seimia Chebbi, Emmanuel Labaronne, Florence M.G. Cavalli, , Eddy Pasquier

This study identifies IRAK1 as a chemoresistance factor in neuroblastoma and shows synergy between IRAK1 inhibition and various drugs in preclinical models.

bioRxiv · Jan 9, 2026 · PreprintCancer Biology